Michigan State University and global theranostics innovator Bold Advanced Medical Future (BAMF, Health) today announced the delivery of two advanced GE PETtrace 890 cyclotrons to the Doug Meijer Medical Innovation Building. Located at the foot of the Medical Mile in downtown Grand Rapids Innovation Park, the arrival classifies the facility as the world’s most modern and advanced dual cyclotron radiopharmaceutical.
The 12,000 square foot radiopharmaceutical, when fully utilized, will meet the growing diagnostic and therapeutic needs of thousands of cancer patients in West Michigan and across the country. The cyclotrons will complement the world’s most advanced molecular imaging clinic and the world’s most advanced theranostics clinic.
“Together, BAMF Health and MSU will advance the precision medicine industry,” said Norman J. Beauchamp Jr., MD, MHS, MSU Executive Vice President of Health Sciences. “Precision medicine offers the ability to create a treatment plan that is unique to each person and the very specific way an illness affects them. This way, each person has the greatest likelihood of results that are meaningful to them personally. This partnership creates the platform on which scientists and clinicians will accelerate the pace by which precision care is accessible and affordable for all. “
“The arrival and installation of these cyclotrons is a milestone for Grand Rapids and will enable the shared vision of BAMF Health and Michigan State University to become a reality,” said Anthony Chang, Ph.D., CEO and founder of BAMF Health The Advances in cyclotron technology have been breathtaking in the recent past. We are proud to partner with MSU to build this exciting new technology and establish Michigan as the leader in theranostic treatment. “
Once installed, the cyclotrons, or particle accelerators, are used in the manufacture of radiopharmaceuticals, which are then delivered to patients for diagnosis and treatment. The cyclotrons produce the radioactive part of the tracer called isotopes. The isotopes are combined with the carrier portion of the radiopharmaceutical within the radiopharmaceutical.
Chang said the clinical value of cyclotrons is essentially limitless when you combine the multitude of isotopes that can be produced by the cyclotrons and the numerous tracers that can be labeled by the radiopharmaceutical team. The novel radiopharmaceuticals that BAMF Health is bringing to market are administered in the BAMF Health clinics in the Doug Meijer Medical Innovation Building, adjacent to the Radiopharmaceuticals, in order to fully exploit their high-performance capabilities.
Funding for the cyclotrons was supported by a philanthropic donation of $ 19.5 million University of Human Medicine by Doug Meijer and the Meijer Foundation at the end of 2019. The donation was intended to support the cyclotron-equipped radiopharmacy and innovative PET scanners.
“The arrival of the cyclotrons is a symbolic first step to save lives and improve the quality of life for thousands of people with prostate cancer,” said Meijer. “These cyclotrons are to scale and can produce multiple isotopes, the remarkable cancer control technology that is the first step in treatment. I am living proof that this technology works. “
Michigan State University and BAMF Health, Inc. have partnered with a focus on advancing the use of molecular imaging and theranostics in the diagnosis and treatment of diseases and conditions.
BAMF Health will pursue diagnostic and therapeutic applications for late-stage prostate cancer and neuroendocrine cancer. Future capabilities include applications to treat various cancers, Alzheimer’s disease, Parkinson’s disease, endometriosis, chronic pain, PTSD, depression, and heart disease.
Anderson Peck, CTO and co-founder of BAMF Health, led the design of the state-of-the-art radiopharmaceutical to ensure that the possibilities for developing novel tracers were limitless. Anderson, along with Matt DeLong, VP Radiopharmacy, has assembled a remarkable team of experts dedicated to operationalizing the facility and energizing the cyclotrons to provide the best possible care to patients in the community and surrounding areas.